Port implantation-related bloodstream infection caused by Wickerhamomyces myanmarensis: A case report.

Q3 Medicine

Current Medical Mycology Pub Date : 2023-03-01 DOI:10.18502/CMM.2023.150671

Ali Aminasnafi, Sadegh Khodavaisy, Maryam Moslem, Marziye Esmaeilpour Jouneghani, Fatemeh Sarbandi, Mahsa Falahatinejad, Bahareh Bashardoust, Hamid Badali, Neda Kiasat

{"title":"Port implantation-related bloodstream infection caused by Wickerhamomyces myanmarensis: A case report.","authors":"Ali Aminasnafi, Sadegh Khodavaisy, Maryam Moslem, Marziye Esmaeilpour Jouneghani, Fatemeh Sarbandi, Mahsa Falahatinejad, Bahareh Bashardoust, Hamid Badali, Neda Kiasat","doi":"10.18502/CMM.2023.150671","DOIUrl":null,"url":null,"abstract":"Background and purpose: Wickerhamomyces myanmarensis is a new opportunistic yeast previously named Pichai myanmarensis, which belongs to the order Saccharomycetales. Since its discovery, one environmental isolate of W. myanmarensis has been reported from Myanmar, and one clinical sample from Iran.Case report: We report a case of bloodstream infection related to an implantable venous access port. W. myanmarensis was isolated from patient's blood after chemotherapy, which was meant to control and heal T-cell lymphoblastic lymphoma. Broth dilution minimum inhibitory concentrations were performed according to the CLSI M27-A3 document. The patient recovered with intravenous voriconazole and was discharged with the recommended prescription of oral voriconazole as a maintenance drug.Conclusion: So far, only one case of W. myanmarensis fungemia has been reported in the world in 2019. This is the second case of bloodstream infection with this yeast from a patient undergoing chemotherapy in Iran.","PeriodicalId":10863,"journal":{"name":"Current Medical Mycology","volume":"9 1","pages":"32-35"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590188/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Mycology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/CMM.2023.150671","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: Wickerhamomyces myanmarensis is a new opportunistic yeast previously named Pichai myanmarensis, which belongs to the order Saccharomycetales. Since its discovery, one environmental isolate of W. myanmarensis has been reported from Myanmar, and one clinical sample from Iran.

Case report: We report a case of bloodstream infection related to an implantable venous access port. W. myanmarensis was isolated from patient's blood after chemotherapy, which was meant to control and heal T-cell lymphoblastic lymphoma. Broth dilution minimum inhibitory concentrations were performed according to the CLSI M27-A3 document. The patient recovered with intravenous voriconazole and was discharged with the recommended prescription of oral voriconazole as a maintenance drug.

Conclusion: So far, only one case of W. myanmarensis fungemia has been reported in the world in 2019. This is the second case of bloodstream infection with this yeast from a patient undergoing chemotherapy in Iran.

Abstract Image

查看原文本刊更多论文

缅甸Wickehamomyces myanmarnsis引起的与港口植入相关的血液感染：一例报告。

背景与目的：缅甸Wickehamomyces myanmarensis是一种新的机会酵母，原名Pichai myanmarnsis，隶属于糖菌目。自发现以来，已从缅甸报告了一种缅甸白热病的环境分离物，并从伊朗报告了一份临床样本。病例报告：我们报告了一例与植入式静脉入口有关的血液感染病例。缅甸W。在化疗后从患者血液中分离出来，旨在控制和治愈T细胞淋巴母细胞淋巴瘤。根据CLSI M27-A3文件进行肉汤稀释最小抑制浓度。患者通过静脉注射伏立康唑康复，并在推荐的口服伏立康唑维持药物处方下出院。结论：到目前为止，2019年全球仅报告了一例缅甸W。这是伊朗第二例接受化疗的患者血液中感染这种酵母的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊